

Life feels good.

Founded
2002

Location
Derio, Bizkaia, Spain

Main Focus
Cardiology, Endocrinology, Hepatology,
Gastroenterology, Internal Medicine,
Nephrology, CNS, Nutrition.

About Rubió Metabolomics

Rubió Metabolomics is a biotech company specialized in the discovery, validation and commercialization of metabolomics-based diagnostics, with a strong focus on liver and metabolic diseases such as MASLD / MASH, obesity and diabetes. Building on more than 20 years of research in the field, the company has developed proprietary platforms that enable the identification of novel biomarkers and the creation of non-invasive tests for early detection, patient stratification and disease monitoring.

Rubió Metabolomics is committed to advancing personalized medicine and supporting clinical research worldwide, providing innovative solutions that improve patient care and accelerate the development of new therapies.

International Alliances and Partnering Strategy

Rubió Metabolomics wants to establish international partnerships for its proprietary diagnostic OWLiver® Test, already commercialized in the US through Cima Sciences, a Rubió Group company, while also offering advanced metabolomics services and complementary solutions such as the Liposcale® test to hospitals, CROs and pharmaceutical companies.

Contact details:

Rubió Metabolomics, S.L.U.
Parque Tecnológico de Bizkaia
Edif. 502, pl.0
48160 Derio, Bizkaia, Spain
Tel.: +34 944 318 540
Mob.: +34 650 146 325
www.rubiometabolomics.com

Contact:

afelis@labrubio.com

The Only Non-invasive Test to Identify All Harmful Stages of MASLD

Description

OWLiver® is a blood test performed under fasting conditions, which measures a panel of lipid biomarkers. Such biomarkers reflect the presence of fat, inflammation and fibrosis in the liver and, hence, allow to determine the degree of severity of metabolic dysfunction-associated steatotic liver disease (MASLD). These lipids are determined by ultrahigh-performance liquid chromatography coupled to mass spectrometry (UHPLC-MS).

The relative concentrations of these biomarkers, together with BMI, ALT and AST are analyzed in a software program that generates the OWLiver® final score, which correlates with the liver status and allows to classify the patient into the different stages of MASLD.



Clinical practice

- **MASLD Screening** - To identify patients with MASLD at any stage of the disease for personalized management.
- **Avoid biopsy** - Precise characterization of the disease avoiding biopsy.
- **Clinical trials** - To identify patients who are candidates for clinical trials.
- **Monitoring** - To monitor the disease in patients who are candidates for pharmacotherapy.
- **Complete Diagnosis** - To avoid the combination of non-diagnostic techniques that present heterogeneity and subjectivity of interpretation.

Registration and Marketing Authorization

- The OWLiver® Test is an Annex III (self-marked) IN VITRO DIAGNOSTIC medical device that has been developed and patented complying with directive 98/79/CE.
- CPT / PLA Code 0344U (USA).

The OWLiver® Test complies with current regulations.

Deal Design

- We are looking for partners with a relevant sales structure in Hepatology, Endocrinology, or Gastroenterology, particularly those oriented towards clinical practice in hospitals and clinics, to properly promote the OWLiver® Test.
- Deal design consisting of a Licensing Agreement to promote and market the OWLiver® Test, which serum samples will be processed in a local Central Lab with UHPLC-MS capabilities.
- We are searching for the best Partners to develop trustful, fruitful and long term business partnerships.